Drug intelligence / Profile preview

adalimumab + pamidronate

Development stage: Preclinical
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of adalimumab, a fully-humanized monoclonal antibody that inhibits tumor necrosis factor alpha (TNF-α), and pamidronate, a bisphosphonate with effects on bone cells and anti-inflammatory properties. This combination has shown synergistic efficacy in treating patients with ankylosing spondylitis who have an incomplete response to adalimumab alone.

Targets

FDPS (Farnesyl pyrophosphate synthase)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adalimumab + pamidronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + pamidronate.

Explore the full profile